WCM Investment Management LLC Takes Position in Biohaven Ltd. (NYSE:BHVN)

WCM Investment Management LLC bought a new position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 106,665 shares of the company's stock, valued at approximately $3,816,000. WCM Investment Management LLC owned about 0.11% of Biohaven as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Franklin Resources Inc. raised its stake in Biohaven by 0.5% during the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company's stock valued at $4,206,000 after purchasing an additional 412 shares in the last quarter. KBC Group NV raised its stake in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company's stock valued at $112,000 after purchasing an additional 443 shares in the last quarter. Venturi Wealth Management LLC raised its stake in Biohaven by 19.1% during the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company's stock valued at $156,000 after purchasing an additional 500 shares in the last quarter. FSC Wealth Advisors LLC raised its stake in Biohaven by 3.3% during the fourth quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company's stock valued at $579,000 after purchasing an additional 500 shares in the last quarter. Finally, US Bancorp DE raised its stake in Biohaven by 57.1% during the third quarter. US Bancorp DE now owns 2,173 shares of the company's stock valued at $109,000 after purchasing an additional 790 shares in the last quarter. Institutional investors own 88.78% of the company's stock.

Biohaven Stock Down 1.0 %

BHVN stock traded down $0.44 during trading on Thursday, hitting $41.68. The company had a trading volume of 554,419 shares, compared to its average volume of 931,801. The firm has a market capitalization of $4.21 billion, a P/E ratio of -4.46 and a beta of 1.28. Biohaven Ltd. has a 52-week low of $26.80 and a 52-week high of $62.21. The company has a 50 day simple moving average of $38.63 and a 200-day simple moving average of $42.62.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Sell-side analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insider Buying and Selling

In other Biohaven news, Director John W. Childs bought 29,000 shares of the company's stock in a transaction on Monday, December 30th. The shares were bought at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the acquisition, the director now directly owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. The trade was a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 16.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

BHVN has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. HC Wainwright reissued a "buy" rating and issued a $59.00 target price on shares of Biohaven in a research note on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Biohaven in a research note on Tuesday. They issued a "buy" rating and a $65.00 target price on the stock. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 target price (up previously from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. Finally, TD Cowen increased their target price on shares of Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $63.15.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.